Johan Svensson

List of Publications by Year
in descending order

128 papers	5,038 citations	87888 38 h-index	102487 66 g-index
132 all docs	132 docs citations	132 times ranked	6253 citing authors

#	Article	IF	Citations
1	Bloodâ€brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor proteinâ€Î² in patients with subcortical smallâ€vessel disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12296.	2.4	5
2	Higher thyroid function is associated with accelerated hippocampal volume loss in Alzheimerâ€™s disease. Psychoneuroendocrinology, 2022, 139, 105710.	2.7	4
3	Testosterone associates differently with body mass index and age in serum and cerebrospinal fluid in men. Journal of Internal Medicine, 2022, 292, 684-686.	6.0	3
4	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. PLoS ONE, 2022, 17, e0267298.	2.5	9
5	Low Serum Insulin-like Growth Factor-I Is Associated with Decline in Hippocampal Volume in Stable Mild Cognitive Impairment but not in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 88, 1007-1016.	2.6	1
6	Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 79, 729-741.	2.6	10
7	Insulin-Like Growth Factor-II and Ischemic Strokeâ€”A Prospective Observational Study. Life, 2021, 11, 499.	2.4	1
8	Subclinical hyperthyroidism is associated with increased risk of vertebral fractures in older men. Osteoporosis International, 2021, 32, 2257-2265.	3.1	6
9	Circulating granulocyte colony-stimulating factor and functional outcome after ischemic stroke: an observational study. Neurological Research, 2021, 43, 1013-1022.	1.3	0
10	Cerebrospinal Fluid Sulfatide Levels Lack Diagnostic Utility in the Subcortical Small Vessel Type of Dementia. Journal of Alzheimer's Disease, 2021, 82, 781-790.	2.6	3
11	Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12031.	2.4	9
12	Association Between Levels of Serum Insulin-like Growth Factor I and Functional Recovery, Mortality, and Recurrent Stroke at a 7-year Follow-up. Experimental and Clinical Endocrinology and Diabetes, 2020, 128, 303-310.	1.2	6
13	Circulating levels of vascular endothelial growth factor and postâ€stroke longâ€term functional outcome. Acta Neurologica Scandinavica, 2020, 141, 405-414.	2.1	8
14	Characteristic Biomarker and Cognitive Profile in Incipient Mixed Dementia. Journal of Alzheimer's Disease, 2020, 73, 597-607.	2.6	8
15	Latent Cognitive Profiles Differ Between Incipient Alzheimerâ€™s Disease and Dementia with Subcortical Vascular Lesions in a Memory Clinic Population. Journal of Alzheimer's Disease, 2020, 73, 955-966.	2.6	1
16	Altered thyroid hormone profile in patients with Alzheimerâ€™s disease. Psychoneuroendocrinology, 2020, 121, 104844.	2.7	21
17	Patients with Alzheimerâ€™s Disease Have Increased Levels of Insulin-like Growth Factor-I in Serum but not in Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2020, 75, 289-298.	2.6	10
18	Relationship between Levels of Pre-Stroke Physical Activity and Post-Stroke Serum Insulin-Like Growth Factor I. Biomedicines, 2020, 8, 52.	3.2	2

#	Article	IF	Citations
19	Low CSF/serum ratio of free T4 is associated with decreased quality of life in mild hypothyroidism â€“ A pilot study. Journal of Clinical and Translational Endocrinology, 2020, 19, 100218.	1.4	4
20	Patients with the Subcortical Small Vessel Type of Dementia Have Disturbed Cardiometabolic Risk Profile. Journal of Alzheimer's Disease, 2020, 73, 1373-1383.	2.6	2
21	Growth Hormone and Neuronal Hemoglobin in the Brainâ€"Roles in Neuroprotection and Neurodegenerative Diseases. Frontiers in Endocrinology, 2020, 11, 606089.	3.5	10
22	Identifying the Value of an eHealth Intervention Aimed at Cognitive Impairments: Observational Study in Different Contexts and Service Models. Journal of Medical Internet Research, 2020, 22, e17720.	4.3	7
23	The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimerâ€™s disease risk. Science Translational Medicine, 2019, 11, .	12.4	170
24	Homeostasis model assessment of insulin resistance and outcome of ischemic stroke in non-diabetic patients - a prospective observational study. BMC Neurology, 2019, 19, 177.	1.8	16
25	Liver-derived IGF-I is not required for protection against osteoarthritis in male mice. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E1150-E1157.	3.5	3
26	Synthetic standard aided quantification and structural characterization of amyloid-beta glycopeptides enriched from cerebrospinal fluid of Alzheimerâ€™s disease patients. Scientific Reports, 2019, 9, 5522.	3.3	20
27	Low serum concentration of free triiodothyronine (FT3) is associated with increased risk of Alzheimerâ€™s disease. Psychoneuroendocrinology, 2019, 99, 112-119.	2.7	33
28	Effects of peripheral administration of GH and IGF-I on gene expression in the hippocampus of hypophysectomised rats. Neuroendocrinology Letters, 2019, 39, 525-531.	0.2	4
29	Update on Vascular Cognitive Impairment Associated with Subcortical Small-Vessel Disease. Journal of Alzheimer's Disease, 2018, 62, 1417-1441.	2.6	90
30	Altered levels of circulating insulin-like growth factor I (IGF-I) following ischemic stroke are associated with outcome - a prospective observational study. BMC Neurology, 2018, 18, 106.	1.8	14
31	Deficiency of liver-derived insulin-like growth factor-I (IGF-I) does not interfere with the skin wound healing rate. PLoS ONE, 2018, 13, e0193084.	2.5	15
32	Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 96-107.	2.4	29
33	Mode of GH administration and gene expression in the female rat brain. Journal of Endocrinology, 2017, 233, 187-196.	2.6	7
34	Low serum insulin-like growth factor-I (IGF-I) level is associated with increased risk of vascular dementia. Psychoneuroendocrinology, 2017, 86, 169-175.	2.7	20
35	Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 59, 1017-1026.	2.6	24
36	Seven years of growth hormone (GH) replacement improves quality of life in hypopituitary patients with adult-onset GH deficiency. European Journal of Endocrinology, 2017, 176, 99-109.	3.7	31

#	Article	IF	Citations
37	Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimerâ€™s Disease and Other Neurodegenerative Disorders. NeuroMolecular Medicine, 2017, 19, 154-160.	3.4	18
38	Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment. PLoS ONE, 2017, 12, e0176760.	2.5	18
39	Insulinâ€like growth factor I and risk of incident cancer in elderly men â€“ results from MrOS (Osteoporotic Fractures in Men) in Sweden. Clinical Endocrinology, 2016, 84, 764-770.	2.4	1
40	Liver-derived IGF-I regulates cortical bone mass but is dispensable for the osteogenic response to mechanical loading in female mice. American Journal of Physiology - Endocrinology and Metabolism, 2016, 311, E138-E144.	3.5	12
41	Serum erythropoietin and outcome after ischaemic stroke: a prospective study. BMJ Open, 2016, 6, e009827.	1.9	9
42	Genomewide metaâ€analysis identifies loci associated with <scp>IGF</scp> â€I and <scp>IGFBP</scp> â€3 levels with impact on ageâ€related traits. Aging Cell, 2016, 15, 811-824.	6.7	83
43	A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimerâ€™s disease pathology. Translational Psychiatry, 2016, 6, e952-e952.	4.8	46
44	Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 283-294.	1.3	33
45	Low Circulating Acute Brain-Derived Neurotrophic Factor Levels Are Associated With Poor Long-Term Functional Outcome After Ischemic Stroke. Stroke, 2016, 47, 1943-1945.	2.0	98
46	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2016, 11, 3.	10.8	236
47	Increased diet-induced fatty streak formation in female mice with deficiency of liver-derived insulin-like growth factor-I. Endocrine, 2016, 52, 550-560.	2.3	8
48	Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2016, 7, 34-39.	3.5	60
49	The Gothenburg MCI study: Design and distribution of Alzheimerâ€™s disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 114-131.	4.3	67
50	Alzheimerâ€™s diseaseâ€”subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 95-113.	4.3	42
51	Increased Cerebrospinal Fluid Level ofÂInsulin-like Growth Factor-II in Male Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 48, 637-646.	2.6	40
52	Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease. Neuroscience Letters, 2015, 609, 58-62.	2.1	20
53	Both Low and High Serum IGF-1 Levels Associate With Increased Risk of Cardiovascular Events in Elderly Men. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2308-E2316.	3.6	39
54	Different modes of GH administration influence gene expression in the male rat brain. Journal of Endocrinology, 2014, 222, 181-190.	2.6	11

#	Article	IF	Citations
55	The amyloid-Î² degradation pattern in plasmaâ€"A possible tool for clinical trials in Alzheimer's disease. Neuroscience Letters, 2014, 573, 7-12.	2.1	62
56	Leukocyte telomere length is not associated with mortality in older men. Experimental Gerontology, 2014, 57, 6-12.	2.8	48
57	Liver-derived endocrine IGF-I is not critical for activation of skeletal muscle protein synthesis following oral feeding. BMC Physiology, 2013, 13, 7.	3.6	13
58	Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. Psychoneuroendocrinology, 2013, 38, 1729-1737.	2.7	66
59	Baseline characteristics and effects of ten years of growth hormone (GH) replacement therapy in adults previously treated with pituitary irradiation. Growth Hormone and IGF Research, 2013, 23, 249-255.	1.1	6
60	Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease. Psychoneuroendocrinology, 2013, 38, 1058-1066.	2.7	38
61	Psychosocial health and levels of employment in 851 hypopituitary Swedish patients on long-term GH therapy. Psychoneuroendocrinology, 2013, 38, 842-852.	2.7	14
62	Fifteen years of GH replacement improves body composition and cardiovascular risk factors. European Journal of Endocrinology, 2013, 168, 745-753.	3.7	89
63	Deaths Among Adult Patients With Hypopituitarism: Hypocortisolism During Acute Stress, and De Novo Malignant Brain Tumors Contribute to an Increased Mortality. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1466-1475.	3.6	166
64	Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease. PLoS ONE, 2013, 8, e81989.	2.5	45
65	Both Low and High Serum IGF-I Levels Associate with Cancer Mortality in Older Men. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4623-4630.	3.6	35
66	Importance of circulating IGF-1 for normal cardiac morphology, function and post infarction remodeling. Growth Hormone and IGF Research, 2012, 22, 206-211.	1.1	19
67	Leukocyte Telomere Length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's Disease: A pilot study. Experimental Gerontology, 2012, 47, 179-182.	2.8	44
68	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population. Journal of Alzheimer's Disease, 2011, 24, 537-546.	2.6	68
69	Liver-Derived IGF-I Regulates Mean Life Span in Mice. PLoS ONE, 2011, 6, e22640.	2.5	53
70	Increased Neck Soft Tissue Mass and Worsening of Obstructive Sleep Apnea after Growth Hormone Treatment in Men with Abdominal Obesity. Journal of Clinical Sleep Medicine, 2010, 06, 256-263.	2.6	19
71	Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain. Journal of Alzheimer's Disease, 2010, 20, 1039-1049.	2.6	19
72	Stimulation of both estrogen and androgen receptors maintains skeletal muscle mass in gonadectomized male mice but mainly via different pathways. Journal of Molecular Endocrinology, 2010, 45, 45-57.	2.5	36

#	Article	IF	Citations
73	Safety aspects of GH replacement. European Journal of Endocrinology, 2009, 161, S65-S74.	3.7	36
74	Ten Years of Growth Hormone (GH) Replacement Normalizes Muscle Strength in GH-Deficient Adults. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 809-816.	3.6	68
75	Serum Insulin-Like Growth Factor-I Concentration Is Associated with Leukocyte Telomere Length in a Population-Based Cohort of Elderly Men. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 5078-5084.	3.6	25
76	The Role of Liver-Derived Insulin-Like Growth Factor-I. Endocrine Reviews, 2009, 30, 494-535.	20.1	361
77	The reduction in visceral fat mass in response to growth hormone is more marked in men than in oestrogen-deficient women. Growth Hormone and IGF Research, 2009, 19, 112-120.	1.1	12
78	Liver-derived IGF1 enhances the androgenic response in prostate. Journal of Endocrinology, 2008, 199, 489-497.	2.6	15
79	Baseline Characteristics and the Effects of Two Years of Growth Hormone (GH) Replacement Therapy in Adults with GH Deficiency Previously Treated for Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2531-2538.	3.6	33
80	Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. European Journal of Endocrinology, 2007, 156, 55-64.	3.7	70
81	A 10-Year, Prospective Study of the Metabolic Effects of Growth Hormone Replacement in Adults. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1442-1445.	3.6	111
82	Nonfatal Stroke, Cardiac Disease, and Diabetes Mellitus in Hypopituitary Patients on Hormone Replacement Including Growth Hormone. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3560-3567.	3.6	44
83	Liver-derived IGF-I regulates kidney size, sodium reabsorption, and renal IGF-II expression. Journal of Endocrinology, 2007, 193, 359-366.	2.6	17
84	Growth hormone (GH) replacement therapy in GH deficient adults: Predictors of one-year metabolic and clinical response. Growth Hormone and IGF Research, 2007, 17, 67-76.	1.1	25
85	Management of growth hormone deficiency in adults. Growth Hormone and IGF Research, 2007, 17, 441-462.	1.1	36
86	Liver-derived IGF-I is permissive for ovariectomy-induced trabecular bone loss. Bone, 2006, 38, 85-92.	2.9	38
87	Sleep apnoea and quality of life in growth hormone (GH)-deficient adults before and after 6Âmonths of GH replacement therapy. Clinical Endocrinology, 2006, 65, 98-105.	2.4	31
88	Baseline Characteristics and Effects of Growth Hormone Therapy over Two Years in Younger and Elderly Adults with Adult Onset GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4408-4414.	3.6	33
89	Endocrine, liver-derived IGF-I is of importance for spatial learning and memory in old mice. Journal of Endocrinology, 2006, 189, 617-627.	2.6	62
90	GH secretory pattern in young adults who discontinued GH treatment for GH deficiency and decreased longitudinal growth in childhood. European Journal of Endocrinology, 2006, 155, 91-99.	3.7	4

#	Article	IF	Citations
91	Thigh intermuscular fat is inversely associated with spontaneous GH release in post-menopausal women with abdominal obesity. European Journal of Endocrinology, 2006, 155, 261-268.	3.7	14
92	Healthcare utilization, quality of life and patient-reported outcomes during two years of GH replacement therapy in GH-deficient adults â€“ comparison between Sweden, The Netherlands and Germany. European Journal of Endocrinology, 2006, 154, 843-850.	3.7	40
93	The effects of fiveâ€year growth hormone replacement therapy on muscle strength in elderly hypopituitary patients. Clinical Endocrinology, 2005, 62, 105-113.	2.4	42
94	Liver-derived IGF-I regulates exploratory activity in old mice. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E466-E473.	3.5	13
95	The Anabolic Effects of Growth Hormone (GH) and GH Secretagogues on Bone Mass and Density. Medicinal Chemistry Reviews Online, 2005, 2, 1-9.	0.1	0
96	Adiponectin, Leptin, and Erythrocyte Sodium/Lithium Countertransport Activity, But Not Resistin, Are Related to Glucose Metabolism in Growth Hormone-Deficient Adults. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2290-2296.	3.6	17
97	Growth hormone and the cardiovascular function. Minerva Endocrinologica, 2005, 30, 1-13.	1.8	15
98	Malignant Disease and Cardiovascular Morbidity in Hypopituitary Adults with or without Growth Hormone Replacement Therapy. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3306-3312.	3.6	206
99	Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease. Clinical Endocrinology, 2004, 60, 550-559.	2.4	40
100	Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption. Growth Hormone and IGF Research, 2004, 14, 207-215.	1.1	56
101	Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. Clinical Endocrinology, 2003, 58, 572-580.	2.4	19
102	Effects of GH and insulin-like growth factor-I on body composition. Journal of Endocrinological Investigation, 2003, 26, 823-831.	3.3	9
103	The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms. Growth Hormone and IGF Research, 2003, 13, 1-7.	1.1	3
104	Long-Term Efficacy and Safety of Somatropin for Adult Growth Hormone Deficiency. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2003, 2, 109-120.	1.8	9
105	Growth Hormone Replacement Therapy and Insulin Sensitivity. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1453-1454.	3.6	18
106	Five Years of Growth Hormone Replacement Therapy in Adults: Age- and Gender-Related Changes in Isometric and Isokinetic Muscle Strength. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2061-2069.	3.6	89
107	Effects of Seven Years of GH-Replacement Therapy on Insulin Sensitivity in GH-Deficient Adults. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2121-2127.	3.6	133
108	Increased Orderliness of Growth Hormone (GH) Secretion in GH-Deficient Adults with Low Serum Insulin-Like Growth Factor I. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2863-2869.	3.6	11

#	Article	IF	Citations
109	The Importance of Growth Hormone (GH) and GH Secretagogues for Bone Mass and Density. Current Pharmaceutical Design, 2002, 8, 2023-2032.	1.9	5
110	Effects of Seven Years of GH-Replacement Therapy on Insulin Sensitivity in GH-Deficient Adults. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2121-2127.	3.6	39
111	Effects of Growth Hormone and Its Secretagogues on Bone. Endocrine, 2001, 14, 063-066.	2.2	20
112	Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormoneâ€“insulin-like growth factor I axis in growth hormoneâ€“deficient children. Clinical Pharmacology and Therapeutics, 2001, 70, 91-98.	4.7	29
113	Body Composition and Quality of Life as Markers of the Efficacy of Growth Hormone Replacement Therapy in Adults. Hormone Research in Paediatrics, 2001, 55, 55-60.	1.8	7
114	A Prospective Study of 5 Years of GH Replacement Therapy in GH-Deficient Adults: Sustained Effects on Body Composition, Bone Mass, and Metabolic Indices. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4657-4665.	3.6	196
115	Baseline Characteristics and the Effects of Five Years of GH Replacement Therapy in Adults with GH Deficiency of Childhood or Adulthood Onset: A Comparative, Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4693-4699.	3.6	98
116	Baseline Characteristics and the Effects of Five Years of GH Replacement Therapy in Adults with GH Deficiency of Childhood or Adulthood Onset: A Comparative, Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4693-4699.	3.6	36
117	The Activity of the Hypothalamicâ€Pituitaryâ€Adrenal Axis and the Sympathetic Nervous System in Relation to Waist/Hip Circumference Ratio in Men. Obesity, 2000, 8, 487-495.	4.0	104
118	The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology, 2000, 165, 569-577.	2.6	25
119	A nine-month, placebo-controlled study of the effects of growth hormone treatment on lipoproteins and LDL size in abdominally obese men. Growth Hormone and IGF Research, 2000, 10, 118-126.	1.1	16
120	Growth hormone secretagogues. Expert Opinion on Therapeutic Patents, 2000, 10, 1071-1080.	5.0	6
121	Treatment of Obese Subjects with the Oral Growth Hormone Secretagogue MK-677 Affects Serum Concentrations of Several Lipoproteins, But Not Lipoprotein(a)1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2028-2033.	3.6	15
122	Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677. Clinical Endocrinology, 1999, 50, 451-456.	2.4	6
123	Treatment of Obese Subjects with the Oral Growth Hormone Secretagogue MK-677 Affects Serum Concentrations of Several Lipoproteins, But Not Lipoprotein(a). Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2028-2033.	3.6	9
124	Growth hormone secretagogues astherapeutic agents. Growth Hormone and IGF Research, 1999, 9, 107-109.	1.1	2
125	Treatment with the Oral Growth Hormone Secretagogue MK-677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males. Journal of Bone and Mineral Research, 1998, 13, 1158-1166.	2.8	32
126	Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 362-369.	3.6	68

#	Article	IF	Citations
127	Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure¹. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 362-369.	3.6	148
128	Insulinâ€like growth factorâ€I in growth hormoneâ€deficient adults: relationship to populationâ€based normal values, body composition and insulin tolerance test. Clinical Endocrinology, 1997, 46, 579-586.	2.4	128